title: Dynamics of the emergence of dasatinib and nilotinib resistance in imatinib-resistant CML patients.
authors.forename: F X
authors.initials: FX
authors.lastname: Gruber
authors.forename: T
authors.initials: T
authors.lastname: Ernst
authors.forename: K
authors.initials: K
authors.lastname: Porkka
authors.forename: R A
authors.initials: RA
authors.lastname: Engh
authors.forename: I
authors.initials: I
authors.lastname: Mikkola
authors.forename: J
authors.initials: J
authors.lastname: Maier
authors.forename: T
authors.initials: T
authors.lastname: Lange
authors.forename: A
authors.initials: A
authors.lastname: Hochhaus
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D000069439:Dasatinib; D019008:Drug Resistance, Neoplasm; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D013844:Thiazoles / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D013844:Thiazoles; D000068877:Imatinib Mesylate; C498826:nilotinib; D000069439:Dasatinib